Tysabri Articles
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Tysabri shows positive risk/benefit profile
22 October 2007
Stock Commentary - New York - week to October 15, 2007
22 October 2007
Daclizumab impresses as MS therapy
22 October 2007
Stock Commentary - Europe - week to Oct 8, 2007
15 October 2007
Biogen forecasts 2007 sales growth of 16-18%, and EPS to increase 20% a year to 2010
17 September 2007
UK's NICE recommends Tysabri for severe MS
3 September 2007
Tysabri improves MS sufferers' QOL
3 September 2007
Stock Commentary - Europe - week to Aug 13, 2007
20 August 2007
Elan's 2nd-qtr 2007 loss deepens 56%
6 August 2007
Elan's natalizumab gets CHMP negative opinion
30 July 2007
NICE Oks Biogen/Elan's Tysabri for severe RRMS
9 July 2007
Biogen Idec share repurchase plan
4 June 2007
Stock Commentary - Europe - week to May 28, 2007
4 June 2007
Stock Commentary - New York week to May 28, 2007
4 June 2007
FDA C'tee to review Tysabri for Crohn's
4 June 2007
Biogen's 1st-qtr income climbs 7% to $131M
14 May 2007
Stock Commentary - New York week to April 23, 2007
30 April 2007
Elan's 4th-qtr loss down 55%
5 March 2007
Tysabri for Crohn's disease sBLA submitted to FDA
22 December 2006
Tysabri filed with FDA for Crohn's
22 December 2006
Scottish Medicines Consortium provokes mixed reactions
22 December 2006
Italian drug spending rises 9.2%
20 November 2006
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
Biogen Idec's 3rd-qtr income rockets 476%
13 November 2006
Elan's 3rd-quarter 2006 loss widens 74%
6 November 2006
Elan/Biogen Idec's Tysabri maintains remission in CD patients
30 October 2006
Stock Commentary - Europe - week to Oct 2, 2006
9 October 2006
Biogen/Elan's Tysabri yields strong Ph III data
9 October 2006
Stock Commentary - New York week to Sept 25, 2006
2 October 2006
Stock Commentary - Europe - week to Aug 7, 2006
14 August 2006
Tysabri narrows Elan's 2nd-qtr losses 37%
7 August 2006
Biogen/Elan's Tysabri back on US market, with limits
31 July 2006
Tysabri gets EC approval for relapsing MS
10 July 2006
Stock Commentary - Europe - week to June 12, 2006
19 June 2006
Elan's losses narrow; sees return to profit
15 May 2006
BI's 1st-qtr revenues hit $611M, up 4%
8 May 2006
Elan's Tysabri viewed positively by CHMP
8 May 2006
Good QoL scores for Tysabri
17 April 2006
Tysabri re-enters clinical trial program
3 April 2006
US FDA extends Tysabri review to end of June
27 March 2006
Stock Commentary - New York week to Mar 13, 2002
20 March 2006
Stock Commentary - Europe - week to Mar 13, 2006
20 March 2006
Stock Commentary - Europe - week to Mar 6, 2006
13 March 2006
Biogen Idec/ Elan reveal new Tysabri safety data
13 March 2006
Stock Commentary - Europe - week to Feb 20, 2006
27 February 2006
Biogen Idec sees 8% 4th-qtr 2005 sales rise
27 February 2006
Elan sees heavy 2005 losses of 317M euros
6 February 2006
Biogen Idec/Elan to receive FDA Tysabri decision by March
16 January 2006
Biogen Idec to cut 17% of jobs in response to Tysabri
19 September 2005
Stock Commentary - New York week to Aug 15
22 August 2005
Stock Commentary - Europe - week to Aug 15
22 August 2005
Stock Commentary - Europe
1 August 2005
Stock Commentary - Europe
11 July 2005
Tysabri Ph III meets endpoint in Crohn's
11 July 2005
Stock Commentary - New York
20 June 2005
Stock Commentary - New York
13 June 2005
A fourth knock for Elan/Biogen's Tysabri?
13 June 2005
Elan retires $240.0 million of 2008 debt
13 June 2005
Stock Commentary - Europe
6 June 2005
Stock Commentary - Europe
16 May 2005
Stock Commentary - Europe
9 May 2005
Biogen: 1st-qtr profit despite Tysabri loss
9 May 2005
Elan's 1st qtr crushed by drug withdrawal
9 May 2005
Stock Commentary - Europe
25 April 2005
Tysabri shows strong results as add-on MS therapy
25 April 2005
Elan again under SEC probe
18 April 2005
Stock Commentary - Europe
11 April 2005
Stock Commentary - New York
11 April 2005
Third patient death linked to Tysabri
4 April 2005
Break-up of Ireland's Elan being mooted?
4 April 2005
US FDA finds no post-marketing report of PML
28 March 2005
Japan stock market week to March 21
28 March 2005
Serono scientists identify MS genes for database
28 March 2005
Stock Commentary - Europe
14 March 2005
Second Tysabri trial fatality confirmed
14 March 2005
Biogen Idec general counsel quits
14 March 2005
Class action against Elan over Tysabri
14 March 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
